Idioma:

Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03

Tsien, Christina, M.D ; Moughan, Jennifer, M.S ; Michalski, Jeff M., M.D., M.B.A ; Gilbert, Mark R., M.D ; Purdy, James, Ph.D ; Simpson, Joseph, M.D., Ph.D ; Kresel, John J., M.D., Ph.D ; Curran, Walter J., M.D ; Diaz, Aidnag, M.D ; Mehta, Minesh P., M.D

International journal of radiation oncology, biology, physics, 2009-03, Vol.73 (3), p.699-708 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03
Autor: Tsien, Christina, M.D ; Moughan, Jennifer, M.S ; Michalski, Jeff M., M.D., M.B.A ; Gilbert, Mark R., M.D ; Purdy, James, Ph.D ; Simpson, Joseph, M.D., Ph.D ; Kresel, John J., M.D., Ph.D ; Curran, Walter J., M.D ; Diaz, Aidnag, M.D ; Mehta, Minesh P., M.D
Assuntos: 3D-CRT ; Adult ; Aged ; Antineoplastic Agents, Alkylating - administration & dosage ; Antineoplastic Agents, Alkylating - adverse effects ; Brain - pathology ; Brain - radiation effects ; Carmustine - administration & dosage ; Carmustine - adverse effects ; CENTRAL NERVOUS SYSTEM ; CHEMOTHERAPY ; Combined Modality Therapy - adverse effects ; Combined Modality Therapy - methods ; Dose escalation ; Drug Administration Schedule ; Feasibility Studies ; Female ; Glioblastoma ; Glioblastoma - drug therapy ; Glioblastoma - radiotherapy ; Glioblastoma - surgery ; GLIOMAS ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; NECROSIS ; Necrosis - pathology ; PATIENTS ; Prospective Studies ; Quality Control ; RADIATION DOSES ; RADIATION HAZARDS ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy Dosage ; Radiotherapy, Conformal - adverse effects ; Radiotherapy, Conformal - methods ; Radiotherapy, Conformal - standards ; Reoperation ; Steroids - administration & dosage ; Supratentorial Neoplasms - drug therapy ; Supratentorial Neoplasms - radiotherapy ; Supratentorial Neoplasms - surgery ; Survival Analysis ; TOXICITY ; Young Adult
É parte de: International journal of radiation oncology, biology, physics, 2009-03, Vol.73 (3), p.699-708
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Purpose To evaluate in a Phase I trial the feasibility and toxicity of dose-escalated three-dimensional conformal radiotherapy (3D-CRT) concurrent with chemotherapy in patients with primary supratentorial glioblastoma (GBM). Methods and Materials A total of 209 patients were enrolled. All received 46 Gy in 2-Gy fractions to the first planning target volume (PTV1 ), defined as the gross tumor volume (GTV) plus 1.8 cm. A subsequent boost was given to PTV2 , defined as GTV plus 0.3 cm. Patients were stratified into two groups (Group 1: PTV2 <75 cm3 ; Group 2: PTV2 ≥75 cm3 ). Four RT dose levels were evaluated: 66, 72, 78, and 84 Gy. Carmustine 80 mg/m2 was given during RT, then every 8 weeks for 6 cycles. Pretreatment characteristics were well balanced. Results Acute and late Grade 3/4 RT-related toxicities were no more frequent at higher RT dose or with larger tumors. There were no dose-limiting toxicities (acute Grade ≥3 irreversible central nervous system toxicities) observed on any dose level in either group. On the basis of the absence of dose-limiting toxicities, dose was escalated to 84 Gy in both groups. Late RT necrosis was noted at 66 Gy (1 patient), 72 Gy (2 patients), 78 Gy (2 patients), and 84 Gy (3 patients) in Group 1. In Group 2, late RT necrosis was noted at 78 Gy (1 patient) and 84 Gy (2 patients). Median time to RT necrosis was 8.8 months (range, 5.1–12.5 months). Median survival in Group 1 was 11.6–19.3 months. Median survival in Group 2 was 8.2–13.9 months. Conclusions Our study shows the feasibility of delivering higher than standard (60 Gy) RT dose with concurrent chemotherapy for primary GBM, with an acceptable risk of late central nervous system toxicity.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03

Tsien, Christina, M.D ; Moughan, Jennifer, M.S ; Michalski, Jeff M., M.D., M.B.A ; Gilbert, Mark R., M.D ; Purdy, James, Ph.D ; Simpson, Joseph, M.D., Ph.D ; Kresel, John J., M.D., Ph.D ; Curran, Walter J., M.D ; Diaz, Aidnag, M.D ; Mehta, Minesh P., M.D

United States: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.